U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H27N3O4S
Molecular Weight 429.532
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AZELOPRAZOLE

SMILES

CC1=C(OCC2COC(C)(C)OC2)C(C)=C(C[S@@+]([O-])C3=NC4=C(N3)C=CC=C4)N=C1

InChI

InChIKey=DWDKHTXMLSZGDL-SSEXGKCCSA-N
InChI=1S/C22H27N3O4S/c1-14-9-23-19(13-30(26)21-24-17-7-5-6-8-18(17)25-21)15(2)20(14)27-10-16-11-28-22(3,4)29-12-16/h5-9,16H,10-13H2,1-4H3,(H,24,25)/t30-/m1/s1

HIDE SMILES / InChI

Molecular Formula C22H27N3O4S
Molecular Weight 429.532
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

E-3710 (Z-215) is a new proton pump inhibitor (PPI). E-3710 irreversibly inhibited H(+),K(+)-ATPase activity in pig gastric vesicles with an acidic internal environment. E-3710 is a long-acting inhibitor of gastric acid secretion and a promising novel therapy for acid-related diseases, such as gastroesophageal reflux disease. E-3710 is metabolized through oxidation, reduction and conjugation. Unchanged E-3710 was excreted in urine at trace levels but was not detected in faces. The major isozyme contributing to the oxidation of Z-215, including the formation of Z-215 sulphone, was CYP3A4. It is useful for treating gastroesophageal reflux disease in all CYP2C19 genotypes. E-3710 is in phase II clinical trial for the treatment of erosive esophagitis and gastro-esophageal reflux.

Approval Year

PubMed

PubMed

TitleDatePubMed
E3710, a new proton pump inhibitor, with a long-lasting inhibitory effect on gastric acid secretion.
2010 Aug
Efficacy and Safety Profile of Z-215 (Azeloprazole Sodium), a Proton Pump Inhibitor, Compared with Rabeprazole Sodium in Patients with Reflux Esophagitis: A Phase II, Multicenter, Randomized, Double-Blind, Comparative Study.
2018
Pharmacokinetics and Pharmacodynamics of Azeloprazole Sodium, a Novel Proton Pump Inhibitor, in Healthy Japanese Volunteers.
2018 Apr
Mass balance and metabolism of Z-215, a novel proton pump inhibitor, in healthy volunteers.
2018 Oct

Sample Use Guides

Once a day within about 30 minutes after breakfast 10, 20, or 40 mg for 8 weeks
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 02:15:32 UTC 2023
Edited
by admin
on Sat Dec 16 02:15:32 UTC 2023
Record UNII
MIR2G6L61B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AZELOPRAZOLE
INN  
INN  
Official Name English
Azeloprazole [WHO-DD]
Common Name English
E-3710 FREE BASE
Code English
azeloprazole [INN]
Common Name English
(R)-2-(((4-((2,2-DIMETHYL-1,3-DIOXAN-5-YL)METHOXY)-3,5-DIMETHYLPYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE
Systematic Name English
Code System Code Type Description
PUBCHEM
17747247
Created by admin on Sat Dec 16 02:15:32 UTC 2023 , Edited by admin on Sat Dec 16 02:15:32 UTC 2023
PRIMARY
INN
10426
Created by admin on Sat Dec 16 02:15:32 UTC 2023 , Edited by admin on Sat Dec 16 02:15:32 UTC 2023
PRIMARY
FDA UNII
MIR2G6L61B
Created by admin on Sat Dec 16 02:15:32 UTC 2023 , Edited by admin on Sat Dec 16 02:15:32 UTC 2023
PRIMARY
NCI_THESAURUS
C174711
Created by admin on Sat Dec 16 02:15:32 UTC 2023 , Edited by admin on Sat Dec 16 02:15:32 UTC 2023
PRIMARY
EPA CompTox
DTXSID50241865
Created by admin on Sat Dec 16 02:15:32 UTC 2023 , Edited by admin on Sat Dec 16 02:15:32 UTC 2023
PRIMARY
CAS
955095-45-1
Created by admin on Sat Dec 16 02:15:32 UTC 2023 , Edited by admin on Sat Dec 16 02:15:32 UTC 2023
PRIMARY
SMS_ID
300000034083
Created by admin on Sat Dec 16 02:15:32 UTC 2023 , Edited by admin on Sat Dec 16 02:15:32 UTC 2023
PRIMARY
WIKIPEDIA
Azeloprazole
Created by admin on Sat Dec 16 02:15:32 UTC 2023 , Edited by admin on Sat Dec 16 02:15:32 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY